Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target

Benzinga Newsdesk www.benzinga.com Negative 94.1%

Neg 94.1% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben reiterates Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and maintains $144 price target.